US 12,303,502 B2
Oral liquid composition comprising ivacaftor
Vardhaman Chandrakant Bafna, Maharashtra (IN); Mahesh Mohanrao Bhadgale, Maharashtra (IN); Mokshada Milind Vable, Maharashtra (IN); and Sweety Rajbahadur Singh, Maharashtra (IN)
Assigned to KINEDEXE UK LIMITED, Hayes (GB)
Appl. No. 17/593,430
Filed by Kinedexe UK Limited, Middlesex (GB)
PCT Filed Apr. 16, 2020, PCT No. PCT/IB2020/053602
§ 371(c)(1), (2) Date Sep. 17, 2021,
PCT Pub. No. WO2020/212898, PCT Pub. Date Oct. 22, 2020.
Claims priority of application No. 201921015579 (IN), filed on Apr. 18, 2019.
Prior Publication US 2022/0160698 A1, May 26, 2022
Int. Cl. A61K 31/47 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/20 (2006.01); A61K 47/26 (2006.01); A61K 47/44 (2017.01)
CPC A61K 31/47 (2013.01) [A61K 9/0053 (2013.01); A61K 9/08 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/20 (2013.01); A61K 47/26 (2013.01); A61K 47/44 (2013.01)] 25 Claims
 
1. A liquid composition comprising:
(a) a solvent system comprising a polyethylene glycol and a hydrogenated vegetable oil; and
(b) a therapeutically effective amount of ivacaftor of Formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof;
wherein the liquid composition is formulated for oral administration.